Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16238270 | 0.85 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL10812910 | 0.85 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL27606981 | 0.82 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL2631604 | 0.82 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL10719606 | 0.82 | DYRK1A (0.46) | ALDH1A1HPGDPIK3CGPIK3CDPIK3CA | |
| SCHEMBL10671313 | 0.81 | MAPT (0.54) | RAB9ANPC1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL27099806 | 0.80 | DYRK1A (0.47) | ALDH1A1HPGDPIK3CGPIK3CDPIK3CA | |
| SCHEMBL27331156 | 0.80 | PIK3CG (0.46) | SMN1; SMN2ALDH1A1HPGDPIK3CGPIK3CD | |
| SCHEMBL8124144 | 0.80 | MAPT (0.50) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL48387 | 0.80 | ALDH1A1 (0.53) | RAB9ANPC1ALDH1A1HPGDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-3426652-B1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | ASTRAZENECA AB (SE) | 2020-12-08 | — | — | US | disclosed |
| WO-2017153527-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| EP-2948442-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| EP-1684745-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20070037813-A1 | Serine Protease Inhibitors | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037813-A1 | Serine Protease Inhibitors | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005054430-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2003099316-A1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0574118-A1 | Polycyclic dyes | ZENECA LIMITED (GB) | 1993-12-15 | — | — | EP | disclosed |
| US-4293703-A | Imidazole or imidazoline substituted ureas | MERCK & CO., INC. (US) | 1981-10-06 | — | — | US | disclosed |
| US-4241072-A | Substituted ureas and processes for their preparation | MERCK & CO., INC. (US) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037813-A1 | Serine Protease Inhibitors | TFPI, SPINT2, SERPINE1 | RAB9A 1875/4885NPC1 2424/4885SMN1; SMN2 4351/4885 |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | RAB9A 917/4885NPC1 2632/4885SMN1; SMN2 2730/4885 |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | PIK3CD, PIK3CG, PIK3CA | RAB9A 605/4885NPC1 1960/4885SMN1; SMN2 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.